The European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, is taking place from the 19–23 October. Stay tuned here for the latest data straight from the experts, including Phase III trial updates, the first prospective study of treatment sequencing in mCRPC, and coverage of all the late-breaking abstracts.

ESMO 2018

19–23 October 2018 | Munich, Germany

ESMO 2018

19–23 October 2018 | Munich, Germany

The European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, is taking place from the 19–23 October. Stay tuned here for the latest data straight from the experts, including Phase III trial updates, the first prospective study of treatment sequencing in mCRPC, and coverage of all the late-breaking abstracts.

Selecting the right combination therapy in HCC: challenges 1:30
Selecting the right combination therapy in HCC: challenges
Jean Frédéric Blanc
More evidence needed to support checkpoint inhibitor use in late-stage cancer 3:23
More evidence needed to support checkpoint inhibitor use in late-stage cancer
Giorgio Scagliotti
Rob Jones reviews: practice-affirming and -changing data in prostate cancer 4:09
Rob Jones reviews: practice-affirming and -changing data in prostate cancer
Robert Jones
Rob Jones reviews: GU Cancer data from ESMO 4:27
Rob Jones reviews: GU Cancer data from ESMO
Robert Jones
Limiting duration of treatment with checkpoint inhibitors: the data 4:11
Limiting duration of treatment with checkpoint inhibitors: the data
Jeffrey Weber
Defining risk profiles of endometrial cancer 1:34
Defining risk profiles of endometrial cancer
Carien Creutzberg
Overview of the Spanish GETNE-TRASGU study 3:10
Overview of the Spanish GETNE-TRASGU study
Rocio Garcia-Carbonero
CheckMate 032: nivolumab/ipilimumab for urothelial carcinoma 2:09
CheckMate 032: nivolumab/ipilimumab for urothelial carcinoma
Jonathan Rosenberg
Hitting back at HCC: future landscape of treatment 1:17
Hitting back at HCC: future landscape of treatment
Jean Frédéric Blanc
Chemoimmunotherapy for bladder cancer: similarties to lung cancer 1:28
Chemoimmunotherapy for bladder cancer: similarties to lung cancer
Jonathan Rosenberg
How to manage elderly patients on immunotherapy 3:14
How to manage elderly patients on immunotherapy
Matti Aapro
The difficulties in treating bladder cancer with immunotherapy 1:10
The difficulties in treating bladder cancer with immunotherapy
Jonathan Rosenberg
Is CAR T-cell therapy for solid malignancies? 1:42
Is CAR T-cell therapy for solid malignancies?
Michel Sadelain
Striking a balance between quantity and quality of life in nmCRPC 5:29
Striking a balance between quantity and quality of life in nmCRPC
Robert Jones
What’s next for next for NETs: novel targeted therapies for neuroendrocrine tumors 6:25
What’s next for next for NETs: novel targeted therapies for neuroendrocrine tumors
Rocio Garcia-Carbonero
Improved subtype characterization of endometrial cancer 2:27
Improved subtype characterization of endometrial cancer
Carien Creutzberg
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals